Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Status:	Completed
Conditions:	Ovarian Cancer, Cervical Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	10/14/2017
Start Date:	April 2010
End Date:	December 2012

A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer

The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of
patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites
to be added.

Inclusion Criteria:

- Have histologically documented diagnosis of ovarian, fallopian or peritoneal cancer
that is platinum resistant.

- Have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual
left ventricular ejection fraction of greater than or equal to the institution lower
limit of normal

- Greater than or equal to 18 years of age

- Have clinically acceptable laboratory screening results

- Have an ECOG performance status of 0 or 1

- Able to tolerate oral medications

Exclusion Criteria:

- Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or
diastolic blood pressure greater than 100mmHg); require two or more antihypertensive
medications to control hypertension (including ACE inhibitors, beta blockers, calcium
channel blockers, or diuretics)

- Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater
than 470 msec

- Have active, acute, or chronic clinically significant infections or bleeding

- Have persistent 2+ protein by urinalysis or a history of nephrotic syndrome

We found this trial at

sites

Princess Margaret Hospital

Toronto, Ontario

from

Toronto,